Key Takeaways:
- Global Adoption Continues: Total procedures grew 16% in Q2 2026, with Ion lung biopsy procedures up 36% year over year.
- Price Projection: Based on current execution, ISRG stock could reach $476 by December 2028.
- Potential Gains: This target implies a total return of 30% from the current price of $367.
- Annual Return: Investors could see roughly 12% annualized growth over the next 2.3 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Intuitive Surgical (ISRG) posted solid Q2 results, with revenue up 19% to $2.89 billion and non-GAAP earnings per share up 28%.
The company placed 468 da Vinci systems and 55 Ion systems during the quarter, both healthy increases from a year earlier.
CEO Dave Rosa said adoption remained strong across the company’s multi-port, single-port, and Ion platforms.
But U.S. procedure growth moderated to 12%, down from recent trends, as some patients delayed elective procedures amid changes in insurance coverage tied to ACA premium subsidies.
CFO Jamie Samath noted the underlying disease burden hasn’t changed, meaning deferred procedures will likely still need treatment eventually.
Outside the U.S., growth stayed strong at 20%, led by India, Italy, Taiwan, and the U.K.
ISRG trades around $367 today, well off its 2025 highs, as investors weigh near-term U.S. procedure softness against the company’s long-term growth story.
See analysts’ full growth forecasts and estimates for ISRG stock (It’s free) >>>
What the Model Says for Intuitive Surgical Stock
Intuitive Surgical makes robotic surgical systems, led by its da Vinci platform, along with Ion, a system used for lung cancer diagnosis.
The company’s growth comes from two places: more hospitals buying systems, and existing systems getting used more often.
The single-port (SP) platform grew procedures 61% in the quarter, powered by strength in Korea and the U.S., where the SP stapler is now used in nearly 60% of eligible cases, up sharply from under 40% last quarter.
Management is also rolling out an extended-use program for surgical instruments starting in 2027, which should lower hospital costs and support broader adoption, particularly for high-volume, lower-complexity procedures.
China remains a challenge, with competitive pricing pressure and slower tender activity weighing on growth there.
Japan, on the other hand, just introduced new reimbursement policies in June that management is cautiously optimistic will support adoption going forward.
Using a forecast of 14.1% annual revenue growth and 37.8% operating margins, our model projects the stock could climb to $476 within 2.3 years. This assumes a 32.4x price-to-earnings multiple, a steep discount to ISRG’s own one-year average of 47.6x.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for Intuitive Surgical stock:
1. Revenue Growth: 14.1%
ISRG grew revenue 20.5% in 2025, above its longer-term ten- and fifteen-year averages of 15.5% and 14%.
Management’s full-year 2026 guidance calls for da Vinci procedure growth of 13.5% to 15.5%, with an expectation of landing near the midpoint.
We’re assuming growth settles closer to 14% as U.S. procedure deferrals gradually ease and international markets continue expanding.
2. Operating margins: 37.8%
Trailing twelve-month operating margin sits at 31.3%, already above the five- and ten-year averages of roughly 28%.
Non-GAAP gross margin guidance for the year sits between 68% and 69%, supported by product cost reductions even as the company absorbs higher input costs like semiconductor memory.
We assume margins improve slightly over current levels as R&D investment continues to grow faster than sales and administrative spending.
3. Exit P/E Multiple: 32.4x
ISRG currently trades at 32.4x forward earnings, a sharp discount to its one-year average of 47.6x and five-year average of 55.3x.
We’re holding the multiple flat rather than assuming a re-rating, since the market appears to be pricing in near-term uncertainty around U.S. procedure deferrals and China’s competitive pricing environment before rewarding the stock with a premium multiple again.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Medical device companies tied to elective procedure volumes can see meaningful swings depending on healthcare policy and patient behavior. Here’s how ISRG stock might perform under different scenarios through December 2030:
- Low Case: If revenue growth slows to 10.7% and net income margins settle at 30.2%, investors could still see a 24.3% total return, or about 5.2% annually.
- Mid Case: With 11.9% growth and 32.5% margins, we expect a total return of 58.6%, or roughly 11.2% annually.
- High Case: If deferred procedures return faster than expected and international markets like Japan and India accelerate, revenue growth could reach 13.1% and margins 34.3%, pushing total returns to 96.6% or about 16.9% annually.
See what analysts think about ISRG stock right now (Free with TIKR) >>>
The spread between these outcomes largely depends on how quickly U.S. patients return to deferred elective procedures, how Japan’s new reimbursement policies play out, and whether China’s competitive and pricing pressures ease over the forecast period.
How Much Upside Does Intuitive Surgical Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
